PIH84 - Daily Dose and Costs Associated With Maintenance Therapy of Topical Testosterone Agents Among Hypogonadal Men

Abstract

PIH84 59.24 mg and risk-adjusted dose PPPD was 113.3%, 113.5%, 126.4%, and 118.7% of RSD for Axiron, AndroGel 1% (non- significant vs. Axiron), AndroGel 1.62% (p<0.001 vs. Axiron), and Testim (p=0.047 vs. Axiron), respectively. Risk-adjusted third-party payer costs PPPD were $7.49, $9.49, $10.39, and $9.59 (all p<0.001 vs. Axiron), respectively. CONCLUSIONS: Maintenance dose as a proportion of RSD was the lowest among Axiron and AndroGel 1% patients, while third- party payer costs for the maintenance dose were lowest among Axiron patients. 14 (6.7%) 74 (12.1%) 35 (14.9%) 64 (11.5%) 0.0305 0.0059 0.0516 PPO 133 (63.6%) 364 (59.3%) 137 (58.3%) 219 (39.2%) 0.2664 0.2501 <0.0001 POS 34 (16.3%) 70 (11.4%) 31 (13.2%) 119 (21.3%) 0.0674 0.3600 0.1186 Other/unknown 28 (13.4%) 106 (17.3%) 32 (13.6%) 156 (28.0%) 0.1909 0.9461 <0.0001 HG b 201 (96.2%) 556 (90.6%) 220 (93.6%) 528 (94.6%) 0.0098 0.2253 0.3789 HG associated conditions c 16 (7.7%) 90 (14.7%) 31 (13.2%) 67 (12.0%) 0.0090 0.0584 0.0841 CCI, Mean (SD) 0.7 (1.2) 1.0 (2.0) 0.8 (1.4) 0.9 (1.9) 0.0736 0.4415 0.3124 Select comorbidities included in the CCI Renal disease 2 (1.0%) 19 (3.1%) 10 (4.3%) 21 (3.8%) 0.0905 0.0324 0.0424 HIV/AIDS 0 (0.0%) 12 (2.0%) 1 (0.4%) 12 (2.2%) 0.0438 1.0000 0.0434 Any testosterone use during baseline period d 113 (54.1%) 157 (25.6%) 57 (24.3%) 260 (46.6%) <0.0001 <0.0001 0.0653